Compare BBDC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBDC | VALN |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.4M | 820.0M |
| IPO Year | 2007 | 2021 |
| Metric | BBDC | VALN |
|---|---|---|
| Price | $9.07 | $8.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $9.67 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 726.9K | 19.7K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | ★ 11.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $281,866,000.00 | $211,089,992.00 |
| Revenue This Year | N/A | $5.08 |
| Revenue Next Year | N/A | $12.53 |
| P/E Ratio | $9.37 | ★ N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $7.66 | $3.62 |
| 52 Week High | $10.85 | $12.25 |
| Indicator | BBDC | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 44.05 |
| Support Level | $8.62 | $8.62 |
| Resistance Level | $9.09 | $9.10 |
| Average True Range (ATR) | 0.13 | 0.29 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 80.73 | 12.25 |
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. Barings employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.